Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Meisel

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Blood|April 22, 2016
The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosisBernd Hartz, Rebecca Marsh, Kanchan Rao, et al.
Haematologica|February 13, 2016
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemiaSandra Preuner, Christina Peters, Ulrike Pötschger, et al.
American Journal of Hematology|June 8, 2026
Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-ThalassemiaSujit Sheth, Selim Corbacioglu, Josu de la Fuente, et al.
Blood|April 29, 2020
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemiaJohannes Schmoellerl, Inês Amorim Monteiro Barbosa, Thomas Eder, et al.
Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2023
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II TrialTim Flaadt, Ruth L Ladenstein, Martin Ebinger, et al.
Blood Advances|November 27, 2024
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUMKrzysztof Kalwak, Laura M Moser, Ulrike Pötschger, et al.
The New England Journal of Medicine|April 24, 2024
Exagamglogene Autotemcel for Transfusion-Dependent β-ThalassemiaFranco Locatelli, Peter Lang, Donna Wall, et al.
Blood Advances|October 25, 2019
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targetsJessica I Hoell, Sebastian Ginzel, Michaela Kuhlen, et al.
The New England Journal of Medicine|April 25, 2024
Exagamglogene Autotemcel for Severe Sickle Cell DiseaseHaydar Frangoul, Franco Locatelli, Akshay Sharma, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Blood|April 22, 2016
The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosisBernd Hartz, Rebecca Marsh, Kanchan Rao, et al.
Haematologica|February 13, 2016
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemiaSandra Preuner, Christina Peters, Ulrike Pötschger, et al.
American Journal of Hematology|June 8, 2026
Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-ThalassemiaSujit Sheth, Selim Corbacioglu, Josu de la Fuente, et al.
Blood|April 29, 2020
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemiaJohannes Schmoellerl, Inês Amorim Monteiro Barbosa, Thomas Eder, et al.
Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2023
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II TrialTim Flaadt, Ruth L Ladenstein, Martin Ebinger, et al.
Blood Advances|November 27, 2024
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUMKrzysztof Kalwak, Laura M Moser, Ulrike Pötschger, et al.
The New England Journal of Medicine|April 24, 2024
Exagamglogene Autotemcel for Transfusion-Dependent β-ThalassemiaFranco Locatelli, Peter Lang, Donna Wall, et al.
Blood Advances|October 25, 2019
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targetsJessica I Hoell, Sebastian Ginzel, Michaela Kuhlen, et al.
The New England Journal of Medicine|April 25, 2024
Exagamglogene Autotemcel for Severe Sickle Cell DiseaseHaydar Frangoul, Franco Locatelli, Akshay Sharma, et al.
Pageof 13